PATENTS &

DRUG CANDIDATES

Cancer Metabolism

January 2021

Curadev announces the publication of its PCT application covering small molecule ACSS2 inhibitors

Immune Oncology & Host Immunity

December 2019

Curadev announces the publication of its  PCT applications claiming ADCs and other conjugates for its small molecule STING activator program

December 2019

Curadev announces the publication of its PCT application covering a unique small molecule STING activator chemotype

December 2018

Curadev announces the publication of three PCT applications covering distinct small molecule STING activator chemotypes

June 2018

Curadev files three PCT applications covering distinct small molecule chemotypes in its STING activator program CDV015

May 2018

Certificates of grant received from major international markets for the Curadev small molecule IDO and TDO dual inhibitor patent

February 2016

Curadev announces the publication of its third PCT application covering small molecule inhibitors of the kynurenine pathway

November 2014

Curadev announces the publication of its  second PCT application covering small molecule inhibitors of the kynurenine pathway

September 2014

Curadev announces the publication of its  first PCT application covering small molecule inhibitors of the kynurenine pathway

Drug Delivery

June 2021

European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter

Read more...

April 2018

Certificates  of grant received from major international markets for the Curadev cyclodextrin derivative patent

January 2015

Curadev Pharma files a PCT application in its sponsored program with the University of Greenwich, UK

 
 

RECOGNITION

August 2021

Curadev is in Industry Outlook Magazine's list of the top 10 Biotechnology companies in India.

Read more...

 

April 2019

Curadev's abstract entitled "CRD5500: LB061 was selected as “The most interesting one for the session on targeted immunotherapeutics presenting the landscape of research in Antibody Drug Conjugate (ADC) and Small Molecule Immunotherapy (SMI)” at AACR meeting held in Atlanta, Georgia.

January 2018

Success story of Curadev was featured on IIT, Kanpur website.

Read more...

May 2017

Curadev was selected as one of India’s "20 India Biotech Companies to Watch in 2017” by a panel of experts at the BioPharma India meeting on Biotech Innovation held in Bengaluru. 

Read more...

January 2017

Curadev was profiled by the-ken.com.

Read more...

Sept 2016

Curadev was profiled by The Economic Times in an article titled -  Global healthcare companies seek to bet on Indian startups for fresh start. 

Read more...

April 2016

Curadev received funding approval from the Department of Biotechnology, India, under its SBIRI scheme

March 2016

20 companies chosen as India's Emerging 20 by London Partners. Leaders of these companies were invited to open the London Stock Exchange. 

Read more...

December 2011

Curadev’s In-House R&D unit received official recognition by the Department of Scientific and Industrial Research (DSIR)

September 2011

Curadev received permission to operate its vivarium from the CPSCEA, Ministry of Environment and Forestry, Government of India

September 2011

Curadev received permission to use radioactivity in its dedicated R&D lab from the Atomic Energy Regulatory Board, Government of India

March 2011

Curadev receives World Bank funding under the Sponsored Research and Development (SPREAD) Programme administered by the Technology Finance Group of ICICI Bank, headed by Mr. Jaisingh Dhummal. The objective of this program is to stimulate technology development through private investment in R&D and strengthen industry & technology institution (TI) collaboration. The Curadev project was selected based on its innovative content, likely impact and commercial value.

 

OUTLICENSING &

STRATEGIC PARTNERSHIPS

April 2020

Curadev and Karyopharm, USA sign a drug discovery collaboration agreement under which Curadev will select a target for co-development until Phase 1 clinical trials before handing the drug candidate over to Karyopharm for further development.

Read more...

March 2020

Curadev and Bayer, Germany, sign a research collaboration and license agreement to develop novel STING antagonists

Read more...

September 2019

Curadev receives first milestone payment from the out-licensing of its novel small molecule STING agonist to Takeda Pharmaceuticals

May 2019

Curadev announces licensing of its patents covering its novel small molecule STING agonists to Takeda Pharmaceuticals

Read more...

April 2015

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Roche  

Read more...

May 2013

Curadev partners its dual kinase inhibitor program with Medivation, Inc, USA

September 2012

Curadev receives first milestone payment in its immune oncology small molecule collaboration with Endo Pharma

October 2011

Curadev signs extensive research collaboration deal with Medivation, Inc, USA

April 2011

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Endo Pharma

ACADEMIC 

COLLABORATIONS

October 2020

Curadev initiates a collaboration with clinicians at Christian Medical College, Vellore to study kynurenine levels in dengue patients

Read more...

July 2020

Curadev initiates a collaboration with Dana Farber Cancer Institute to identify drug combinations and patient populations that would benefit from Curadev’s advanced pre-clinical immune-oncology drug candidates

Read More...

October 2017

UT Southwestern Medical Center in Dallas, USA, and Curadev Pharma, India, announce a translational research partnership to identify small molecule drugs for the treatment of specific cancers. 

Read more...

October 2016

Curadev initiates a collaboration with INSERM’s Professor Pierre Gressens, a leading clinician neuroscientist to identify drug targets underlying CNS pathologies

Read more...

July 2011

Curadev signs research collaboration with the University of Greenwich. to create novel process improvements for a range of commercially valuable pharmaceuticals

Read more...

March 2011

Curadev signs an agreement with the SIDBI incubation Center at the Indian Institute of Technology, Kanpur, (IITK)

Read more...

 

COMPANY &

PEOPLE

September 2021
A tree plantation drive was carried out by the Curadev Team in Noida Authority Park. The aim of the event was to create awareness and protect the environment by motivating everyone to take care of the surroundings we are part of.
View image...


August 2021
As part of its focus on recognizing and promoting excellence, Curadev has sponsored the Gold Medal awarded to the top  ranked Masters student of the Pharmacology & Toxicology department at the National Institute of Pharmaceutical Research and Training at Guwahati (NIPER, Guwahati)
Read more...

August 2021
Curadev has partnered with C-CAMP (Centre for Celluar and Molecular Platforms) for National Bio Entrepreneurship Competition (NBEC), 2021
Read more...

November  2020
Diwali Donation Camp: As part of Personal Social Responsibility (PSR), team Curadev has donated clothing, footwear and stationery at large to NGO "Goonj"

January 2020
Curadev celebrates its 10th anniversary

May 2017
Professor Satyajit Rath has joined Curadev’s Scientific Advisory Board
Read more...

October 2016
Dr. Shyamala Mani has joined Curadev as Director R&D
Read more...

April 2016
Dr. David Pryde has joined Curadev as Director R&D bringing his extensive experience in drug discovery to the team
Read more...

January 2016
Curadev announces the incorporation of Curadev UK

June 2015
Dr. Sourav Basu has joined Curadev as Vice President (R&D)
Read more...
 
October 2012
Curadev Pharma is 1000 days young

 
 

CONFERENCES &

MEETINGS

2021

April: Mr. Manish Tandon was invited as a Guest Speaker in the virtual event celebrating World Intellectual Property Week co-organized by FICPI, INTA, AIPPI, APAA, and Lex Witness

Read more...

 

2020

Senior Representatives of Curadev attended:

 

November: Dr. Arjun Surya gave a talk at the Annual Biological Sciences and Bioengineering (BSBE) Symposium in IIT, Kanpur

 

February: Dr. Arjun Surya was invited as a Guest Speaker in the "International Conference on Drug Discovery" organized at BITS Pilani, Hyderabad from 29th February to 2nd March

Read more...

 

2019

Senior Representatives of Curadev attended:

  • The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of BIO, San Francisco, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), Atlanta, USA

  • The Mastering Medicinal Chemistry Conference, Boston, USA

  • The Annual J.P. Morgan Health Care Conference, San Francisco, USA

 

2018

Senior Representatives of Curadev attended:

  • The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

  • BIO-Europe, Copenhagen, Denmark

  • The Annual BIO meeting, Boston, USA

  • The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), Chicago, USA

  • The Annual J.P. Morgan Health Care Conference, San Francisco, USA

  • Researcher Summit organized by DBT and CRUK

2017

Senior Representatives of Curadev attended:

  • The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

  • The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

  • The Annual BIO meeting, San Diego, USA

  • The Tumor Immunology and Immunotherapy meeting of the in Boston, USA

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), Washington,DC, USA

  • The Annual J.P. Morgan Health Care Conference, San Francisco, USA

  • The Keystone Symposium on Tumor Metabolism and Hypoxia, Whistler, Canada

2016

Senior Representatives of Curadev attended:

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, USA where Curadev and Roche scientists presented a jointly authored poster titled: RG70099: A novel, highly potent dual TDO/IDO1 inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.

  • The Mastering Medicinal Chemistry Conference, Boston, USA

  • The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

  • The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

  • The Annual BIO meeting, San Francisco, USA

2015

Senior Representatives of Curadev attended:

2014

Senior Representatives of Curadev attended:

  • The Tumor Immunology and Immunotherapy meeting of the American Society for Cancer Research (AACR) in Orlando, USA where Curadev presented a poster on a small molecule dual inhibitor of TDO and IDO

  • The Annual BIO meeting, San Diego, USA

  • The Annual BIO Asia International Conference meeting, Tokyo, Japan

  • The Immunotherapy of Cancer (ITOC) conference in Munich, Germany

2013

Senior Representatives of Curadev attended:

  •  The Annual BIO meeting, Chicago, USA